Introduction {#S1}
============

The most common routes of HIV transmission are through the genital and rectal mucosa. The gastrointestinal (GI) tract, as the primary viral replication site and viral reservoir for HIV-1, plays an important role in the viral control and eradication. Recent studies demonstrated that the GI tract harbors over 100 trillion bacteria, which form a unique, and functionally stable community, termed the gut microbiome^[@R1]^. The gut microbiome not only facilitates the breakdown of food for energy metabolism, but also contributes to the development and functionality of the immune system, responses to infections, and even behavioral abnormalities^[@R2]--[@R5]^. The cross-talk between the gut microbiome and intestinal immune system is critical for the maintaining of mucosal homeostasis^[@R2]^.

Though the mechanisms by which commensal bacteria modulate the immune system have not been fully elucidated, recent advances in gut microbiome research revealed that a range of bacteria and their derivatives can influence immune functions through intestinal epithelial cells, mononuclear phagocytes, innate lymphoid cells, and T and B lymphocytes^[@R6]^. A large number of T lymphocytes is present in intestine to perform regulatory and effector functions^[@R7]^. Commensal bacteria and their metabolites in the GI tract can promote different cell subset induction^[@R8]--[@R10]^. Among them, short-chain fatty acid (SCFA) metabolites derived from commensal bacteria can induce intestine FoxP3^+^ Treg cells directly^[@R11]--[@R13]^. Capsular polysaccharide A (PSA) of Gram-negative anaerobic bacteria *Bactericides fragilis* have been shown to be able to induce Treg cells through TLR2 as well^[@R14],\ [@R15]^. Besides T cells, some bacteria can regulate the CC chemokine responsiveness including CCR5 in vitro in monocytes^[@R16]^. Thus, distinct members of the gut microbiome or their metabolites can regulate the prevalence of certain immune cell types, and the immune activation markers on these cells.

It is well documented that the gut mucosal homeostasis is interrupted during HIV/SIV infections. HIV/SIV infections affect the gut microbiome, even in the elite controllers^[@R17]^, and the altered gut microbiome in turn leads to general immune activation via bacterial translocation^[@R18]--[@R23]^. However, it is not known whether the reciprocal is true, that the gut microbiome affects susceptibility to HIV/SIV infection. As immune activation also affects the HIV/SIV susceptibility, this raises the interesting question whether naïve animals with different gut microbiomes will have different risk of HIV/SIV infection via the modulation of local mucosal immune activation status. In this study, we sought to investigate the associations of gut microbiome with rectal immune activation markers and HIV/SIV rectal transmission using two cohorts of naïve rhesus macaques from either Morgan Island or Alpha Genesis Inc. Coming from different sources, the two naïve cohorts displayed different gut microbial compositions, which correlated with the viral target cells and with the immune activation markers/status in the colorectal mucosa. Ex vivo treatment of PBMCs with heat-killed fecal bacterial samples from these two cohorts led to different expression levels of immune activation markers on CD4^+^ T cells. When we challenged these macaques simultaneously with repeated low-dose of SHIVSF162P4 virus via the intrarectal route, we observed that they had significantly different rates of infection (47% vs 21%, \*P=0.04). In addition, the viral target cells and the immune activation status in the colorectal mucosa inversely correlated with the number of exposures needed for the animals to get infected. Through these associations and the ex vivo experiment, our data suggested that the different gut microbiota might affect the infection risk of HIV-1 via the rectal mucosal immune activation status, including the availability of viral target cells. Though commensal bacteria have been shown to be involved in modulating immune responses in the GI tract, this is the first demonstration of the association of the gut microbiome with susceptibility to HIV/SIV viral infection in a macaque model. This could have profound implications to develop strategies to prevent HIV-1 transmission.

Results {#S2}
=======

Two cohorts of naïve macaques, which demonstrated different SHIV viral infection rates, had different viral target cells in the rectal mucosa {#S3}
---------------------------------------------------------------------------------------------------------------------------------------------

Two cohorts of naïve Indian rhesus macaques were obtained from two different sources: the N7 group of 7 animals were wildly captured from Morgan Island, while the N11 group of 11 animals were inbred from Alpha Genesis Inc ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). Before administration of SHIVSF162P4 viral challenges, the N7 and the N11 group of macaques were cohoused in the same room for 5 months. The repeated low-dose simian/human immunodeficiency virus (SHIV) challenge macaque model has been widely used to assess the HIV susceptibility^[@R24],\ [@R25]^. In this study, we utilized this model to test the viral susceptibility of these two cohorts of naïve macaques. We gave the macaques low-dose SHIVSF162P4 virus intrarectally every week for 8 weeks. After 8 SHIV challenges, 17 out of 18 animals were infected, and the infection rate for all the animals was 27%. However, we observed that these two cohorts demonstrated significantly different infection rates. N7 had an infection rate of 47% per exposure, while N11 had only a 21% rate. Even with the small number of animals in each cohort, they showed a significant difference in viral acquisition (P=0.04, [Figure 1a](#F1){ref-type="fig"}).

To explore the possible cause of this difference, we examined different cell subsets and the immune activation markers that are associated with the immune regulation in the colorectal tissues. Since CD4^+^ regulatory T cells (T~regs~) are present at higher frequencies in the colon lamina propria (LP) than in other organs^[@R26]^, and have important implications in inflammatory bowel disease, we first measured the frequencies of Tregs in the rectal mucosa. We found that the frequency of CD25^+^FOXP3^+^ cells among CD4^+^ T cells was about 4%, and no significant difference in Treg cell frequencies in the colon LP between the two cohorts were observed ([Figure 1b](#F1){ref-type="fig"}, [Supplementary Figure 1](#SD1){ref-type="supplementary-material"}).

We then tested myeloid-derived suppressor cells (MDSC), which not only are important immune regulators to suppress the immune activation, but also have been identified as viral target cells in the SIV-infected macaques^[@R27]^. We measured two major subsets of MDSCs in the colorectal LP, and found that neither CD14^+^ MDSCs nor CD15^+^ MDSCs showed any significant difference between the two cohorts ([Figure 1c--d](#F1){ref-type="fig"}, [Supplementary Figure 2](#SD1){ref-type="supplementary-material"}). MDSC did not correlate with viral acquisition either.

We next measured the CD4^+^ T viral target cell (CD4^+^CCR5^+^Ki67^+^ T) frequencies in the blood and gut mucosal tissues based on our and other's studies^[@R28]--[@R30]^. We have shown previously that the viral target cells in the rectal mucosa determined the viral loads and viral eclipse time once the animals were infected in our previous study, while Carnathan et al found that the activated CD4^+^CCR5^+^ T cells in the rectum predicted increased SIV acquisition in SIVGag/Tat-vaccinated rhesus macaques^[@R28]--[@R30]^. Indeed, we found that the original more susceptible N7 group had more activated CD4^+^CCR5^+^Ki67^+^ T cells (viral target cells) in PBMC (P=0.003), and in the rectal intraepithelial lymphocytes IEL (P=0.056) than those in the more resistant group of N11([Figure 1e--f](#F1){ref-type="fig"}, [Supplementary Figure 3](#SD1){ref-type="supplementary-material"}). Though the frequency of viral target cells in the rectal mucosa of the N7 group only showed trend of higher than that of the N11 group, it significantly correlated inversely with the number of intrarectal exposures needed for viral infection ([Figure 1h](#F1){ref-type="fig"}). Viral target cells in the PBMC showed a trend, but did not significantly correlate with viral acquisition ([Figure 1g](#F1){ref-type="fig"}). This supported the conclusion that the viral target cells in the rectal mucosa played an important role in determining viral transmission.

The mucosal immune activation status was significantly different in the two cohorts of macaques {#S4}
-----------------------------------------------------------------------------------------------

Besides viral target cells, we further explored whether there were other immune activation markers that could be used to more precisely define the immune activation status of the rectal mucosa. We have measured 5 immune activation markers (Ki67, CD69, CD38, CCR5 and HLA-DR), which have been associated with HIV-1 infections, in three cell subsets (CD4^+^T, CD8^+^T and CD14^+^monocytes). To generalize the idea, we analyzed the data using an unsupervised principal component analysis (PCA) with Qlucore Omics Explorer^[@R31]^. With the first three PCA components explaining 67% of the total variance, the generated PCA plot revealed that the N7 and the N11 groups had distinct immune activation status ([Figure 2a](#F2){ref-type="fig"}). Highlighting a common signature of each cohort, the parameters listed in [Figure 2b](#F2){ref-type="fig"} accounted for most of the difference in the colorectal mucosa. The more resistant group of N11 had higher expression of CD38 in both CD4 and CD8 T cells, as well as higher HLA-DR expression in CD14^+^ monocytes, while the more susceptible cohort N7 had higher expression of CCR5 in all three cell types (CD4, CD8 T cells and CD14^+^ monocytes), and higher Ki67 expression in CD4 T cells. This suggested that the immune signature of the two cohorts primarily involved the expression of CCR5, Ki67, CD38 and HLA-DR. Overall, the two cohorts of macaques had different expression levels of immune activation markers on T cells and myeloid cells in the rectal mucosa.

We then exported the PCA-1 of the immune activation markers, and compared them in the two naïve groups. As predicted, the N7 and N11 groups had significantly different PCA-1, which also showed association with number of exposures needed for infection ([Figure 2c--d](#F2){ref-type="fig"}).

To summarize, SHIV viral susceptibility was associated with two markers: 1) the prevalence of activated rectal viral target cells, and 2) the PCA-1 of multiple immune activation markers in the rectal mucosa. Both could be used as surrogate markers to monitor the immune activation status.

Distinct bacterial taxa composition of fecal microbiome in the two naive cohorts {#S5}
--------------------------------------------------------------------------------

Because the two cohorts of naïve groups came from two different sources, we hypothesized that the difference in immune activation in the GI tract might be due to distinct gut microbiota. To test this hypothesis, we examined the gut microbiome by 16S rDNA MiSeq. Total bacterial DNA was extracted from the fecal samples collected one-week before the serial challenges. Using the MiSeq protocol, we obtained an average of 108,096±3,121 operational Taxonomic Units (OTUs) per sample, which were subjected to subsequent analysis ([Supplementary Table 2](#SD1){ref-type="supplementary-material"}). We further examined the bacterial compositions at different levels, and investigated whether the gut microbiome was associated with local mucosal immune activation or SHIV susceptibility.

At the phylum level, 17 phyla have been identified. A compositional look at this level revealed that the top four phyla: *Bacteroidetes, Firmicutes, Proteobacteria*, and *spirochaetes* represented more than 90% of the total bacteria ([Figure 3a--b](#F3){ref-type="fig"}). Among these four phyla, *Firmicutes* were significantly higher in the N11 group (the resistant cohort) than in the N7 group ([Figure 3c](#F3){ref-type="fig"}). Furthermore, *Firmicutes* correlated inversely with a low frequency of Ki67^+^CCR5^+^CD4^+^T cells (SHIV target cells) in the rectal mucosa and showed a correlation with mucosal immune activation PCA-1 ([Figure 3c](#F3){ref-type="fig"}), suggesting that *Firmicutes* might influence the frequencies of viral target cells and immune activation markers in the gut mucosa. However, Firmicutes did not correlate with numbers of exposures to SHIV virus, suggesting they unlikely affected the SHIV viral transmission directly ([Supplementary Figure 4](#SD1){ref-type="supplementary-material"}). The other top three phyla: *Bacteroidetes, Proteobacteria*, and *spirochaetes* did not differ between the two cohorts ([Figure 3d](#F3){ref-type="fig"}).

Gut microbiota composition at the genus level showed that the bacterial PCA correlated with viral target cells/immune activation in the rectal mucosa {#S6}
-----------------------------------------------------------------------------------------------------------------------------------------------------

We then zoomed in on the bacteria compositions at the genus level, in which over 200 taxa were identified. We did not find significantly different taxa abundance between the two cohorts of macaques ([Figure 4a](#F4){ref-type="fig"}). However, the PCA plot of the gut bacteria showed different microbial compositions of the two cohorts, even after more than 5 months of co-housing ([Figure 4b](#F4){ref-type="fig"}). Exporting the bacteria PCAs, we found that PCA-1, representing 14% of total taxa, showed a correlation or a trend of correlation with mucosal immune activation PCA-1, or Ki67^+^CCR5^+^CD4^+^T SHIV target cells ([Figure 4c](#F4){ref-type="fig"}). However, bacterial PCA-1 did not directly correlate with the number of viral exposures.

Among the taxa at the genus level, Anaerovibrio, Bacteroides, Bulleidia, Ruminococcus, Mogibacterium, and Symbiobacterium were significantly higher in the N11 group, while Anaeroplasma, Burkholderia, syntrophobacter were significantly higher in the N7 group ([Figure 5](#F5){ref-type="fig"}). We also tried to identify the specific bacteria that might be associated with the viral infection. *Mogibacterium*, *Hydrogenoanaerobacterium*, and *orientia* showed corrections with viral acquisition directly ([supplementary Figure 5](#SD1){ref-type="supplementary-material"}).

The different sources of the two cohorts of animals might account for the different gut microbiome they had. However, we noticed that the average age of N11 cohort was relatively younger than that of the N7 cohort group ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). In the N7 group, three animals had ages similar to those of the N11 group, while the other 4 were older. Since a previous study has found that old age is associated with microbial dysbiosis and systemic inflammation^[@R32]^, to determine whether age played any roles in determining immune activation and the composition of the gut microbiome, we have included another 21 animals, which were obtained from the same source (Morgan Island) and which arrived in the facility in the same shipment at the same time as the N7 group. As the macaques were all relatively young adults (aging from about 3--5.5 years), not elderly, we did not find any correlations between age and viral target cells in the rectal mucosa or PBMC ([Supplementary Figure 6 a--b](#SD1){ref-type="supplementary-material"}). Moreover, fecal samples from these 21 animals and the N7 groups were collected and sequenced for microbiome when they first arrived in the facility before any treatment or challenge. We did not observe any associations between age and the composition of gut microbiome either ([Supplementary Figure 6 c--e](#SD1){ref-type="supplementary-material"}). All animals in the N11 cohort were females, whereas there were both males (N=5) and females (N=2) in the N7 cohort. To test whether gender was a major factor in the observed differences in gut bacteria, we analyzed the data and did not find any gender-specific differences in gut bacteria: the 2 values of the females lay within the range of the 5 values of the males for PCA-1 and the Firmicute frequencies (p=0.86 for each).

The ratio *Bacteriodes/Prevotella* inversely correlated with gut mucosal immune activation {#S7}
------------------------------------------------------------------------------------------

Consistent with a previous report that *Prevotella* but not *Bacteroides* is the more common genus in the gut of macaques^[@R33]^, we found that 6 out of 7 macaques from N7 group hardly had any *Bacteriodes* in the gut (less than 1000 units), whereas more than half of the N11 group had more than 1000 units of *Bacteriodes* ([Figure 5](#F5){ref-type="fig"}). Since the ratio of *bacteroides* to *prevotella* has been previously shown lower than in HIV-1 infected patients^[@R20]^, we compared this ratio in the two cohorts. Notably, the two cohorts had different abundance of Bacteriodes, *Prevotella*, and the the ratio of *bacteroides* to *prevotella* was significantly lower in the more susceptible cohort, as in the HIV-infected patients^[@R20]^([Figure 6a](#F6){ref-type="fig"}). Though the ratio of *bacteroides* to *prevotella* did not directly correlate with number of viral challenges needed for the animals to get infected, it did show a trend of inverse correlation with viral target cells and did show a significant association with mucosal immune activation PCA-1 ([Figure 6b--c](#F6){ref-type="fig"}).

We further identified the *prevotella* and *bacteroides* species that were different between the two cohorts. Among the 10 species that had more than 1% of the total genus *prevotella*, *P. copri* ranked first and comprised 65% of the genus *prevotella* ([Figure 7a](#F7){ref-type="fig"}). However, only *P. histicola, P. brevis, P. Oris and P. albensis* showed significant differences between the N7 and N11 groups ([Figure 7b](#F7){ref-type="fig"}). Nevertheless, none of them correlated with Ki67^+^CCR5^+^CD4^+^T cells in the rectal mucosa or mucosal immune activation PCA-1. In the genus *bacteroides*, the top four species: *B. intestinalis, B. xylanolyticus, B. plebeius, and B. acidifaciens* comprised more than 80% of the total genus ([Figure 7c](#F7){ref-type="fig"}). *B. intestinalis, and B. plebeius* showed significant differences between the N7 and N11 groups ([Figure 7d](#F7){ref-type="fig"}). *B. intestinalis* was associated with both Ki67^+^CCR5^+^CD4^+^T cells in rectal mucosa and the mucosal immune activation PCA-1 ([Figure 7e](#F7){ref-type="fig"}). We then asked whether mucosal viral target cells or immune activation PCA-1 correlated with the ratios of *B. intestinalis* to different species of *prevotella*. The ratios with all four species demonstrated associations with viral target cells or immune activation PCA-1 in the rectal mucosa ([Figure 7f](#F7){ref-type="fig"}). Overall, at the species level, *B. intestinalis* not only differed in two naïve cohorts, but also was associated with viral target cells and mucosal immune activation PCA-1. Future studies should address whether *B. intestinalis* and its metabolites modulate the viral target cells and/or CCR5 expression on T and myeloid cells.

Fecal samples from N7 and N11 groups induced different levels of immune activation markers on CD4^+^T cells of naïve PBMCs {#S8}
--------------------------------------------------------------------------------------------------------------------------

The correlations between immune activation and gut microbiome could not prove that the microbiome differences were causing the immunological differences. To investigate the potential impact of gut microbiome on immune activation markers, we treated naive PBMCs with fecal samples from each animal of the N7 and N11 groups, and compared the expression levels of immune activation markers on T cells, especially the viral target CD4^+^ T cells (CCR5^+^Ki67^+^). After co-culture, the frequencies of Ki67, CD38, CD69, and CCR5^+^Ki67^+^ were significantly lower on CD4^+^ T cells stimulated with fecal samples from N11 group than those from N7 group, while the expression level of CCR5 and HLA-DR alone on CD4^+^ T cells were similar ([Figure 8](#F8){ref-type="fig"}). Importantly, the frequency of CD4^+^ T cells was not differentially affected by the microbiota from the two groups of macaques, indicating that the lower levels of activation by the N11 group fecal samples was not due to gross toxicity to CD4^+^ T cells ([Figure 8f](#F8){ref-type="fig"}). Most of the immune activation markers on CD8^+^ T cells did not significantly differ between N7 and N11 groups after stimulated with fecal samples from each group ([Figure 8](#F8){ref-type="fig"}, [supplementary Figure 7](#SD1){ref-type="supplementary-material"}). However, the CD8^+^ T cell frequency among the CD45^+^ live cell gating was significantly decreased after co-culture with fecal samples from N11 group, compared to the N7 group. Overall, exposure naïve PBMC CD4^+^ T cells to fecal bacteria from N7 and N11 cohorts resulted in significantly different expression levels of immune activation markers, consistent to the expression patterns observed in vivo. This result supported the interpretation that the gut bacterial composition might contribute to the immune phenotypes and/or infection outcomes of this study and could explain the correlations observed.

Discussion {#S9}
==========

Here we have found that rhesus macaques from different sources have different microbiota, which correlate with levels of immune activation in the rectal mucosa, which in turn affect the susceptibility of the macaques to rectal transmission of SIV. We observed that the more susceptible N7 group had significantly more activated CD4^+^CCR5^+^Ki67^+^ T cells in the rectal mucosa than the more resistant group of N11. The groups also differed significantly by principal component analysis of other activation markers. Moreover, these animals demonstrated different HIV/AIDS susceptibility in a low-dose SHIV challenge model. The prevalence of these activated rectal CD4 T cells and the PCA-1 of other immune activation markers in the rectal mucosa correlated with the number of challenges required to infect. After sequencing 16s rRNA, the preliminary principal component analysis of the gut taxa showed that these two cohorts had different microbial compositions, which were associated with gut immune activation, providing more activated viral target cells for SHIV infection. Significantly lower ratios of *Bacteroides* to *Prevotella*, and significantly lower levels of *Firmicutes* were found in the susceptible N7 cohort. These parameters also inversely correlated with high levels of immune activation markers as well as viral target CD4^+^T cells in rectal mucosa. In field epidemiology studies, genital microbiome, from either female^[@R34][@R35]^ or male^[@R36]^ genital tracts, has been correlated with HIV acquisition risk. Furthermore, vaginal bacteria have been shown to affect the microbicide efficacy against HIV infection via bacterial metabolism of the microbicide, leading to tenofovir depletion^[@R37]^. Whether gut microbiome will do the same in the case of intrarectal infection is an open question. Our study demonstrated for the first time that macaques with distinct gut microbiota and immune activation markers had different endogenous mucosal SHIV infection risks when challenged intrarectally with identical doses of the same SHIV.

Chronic immune activation in HIV/AIDS is associated with high viral loads and CD4 T cell depletion, and can determine the progression of AIDS disease^[@R38]^. Mucosal immune activation status, especially the viral target cells in the colorectal mucosa, plays an even more important role in determine the outcomes of HIV-1 infection than the corresponding peripheral parameters do. This prompted us to investigate the immune activation status in the colorectal mucosa in the two naïve cohorts. Indeed, the two cohorts had different levels of mucosal immune activation markers, which correlated with viral susceptibility. To identify the cause of these differences between the two cohorts of naïve animals, we proposed that the gut microbiome might be responsible. In HIV infection, gut microbial translocation has been implicated as a major driving force to contribute to chronic immune activation^[@R39]^. The bacteria or the bacterial products moving from the gut lumen to lamina propria (LP) and systemic circulation interrupted the delicate balance between immunogenic and tolerogenic intestinal immune responses. Furthermore, plasma bacterial lipopolysaccharide (LPS) levels correlated with measures of innate and adaptive immune activation in chronically HIV-infected individuals and in SIV-infected rhesus macaques^[@R40]^. In naïve animals, we do not expect to observe as much gut microbial translocation as in the HIV/SIV infected ones. Nevertheless, the gut microbiome and its metabolites can interact with the host immune cells in the gut mucosa via a diversity of receptors, including Toll-like receptors (TLRs), NOD-like receptors (NLRs), and C-type lectin receptors, such as dectin 1, dectin 2 and macrophage-inducible C-type lectin^[@R41][@R42][@R43]^. Upon sensing bacteria and their metabolites, specific gut microbiota are able to transduce specific signals in the host immune cells, and affect the immune activation of these cells. After exposure to *Prevotella stercorea*, naïve LP CD4^+^T cells upregulated Ki67, p38 MAPK, and HIV viral DNA replication host co-factors, which led to increased HIV viral susceptibility in vitro^[@R44]^. In the current in vivo study, we found that two cohorts of naive animals with different gut microbiomes and immune activation markers, that correlated with each other, had different infection rates for SHIV challenge. However, correlation alone can never prove causation. To find possible further evidence for a causative effect, we did an ex vivo co-culture experiment to evaluate the impact of the gut microbiome community and its metabolites on T cell immune activation. We found heat-killed fecal samples from the more susceptible cohort N7 group induced overall higher expression levels of immune activation markers (Ki67, CD38, CD69) on CD4^+^ T cells from naïve PBMCs. Furthermore, the frequency of viral target cells, Ki67^+^CCR5^+^ CD4^+^T cells, was significantly higher in PBMCs treated with fecal bacterial samples from the N7 group than those from the N11 group. Though we did not dissect which bacteria were responsible for the changes, these data suggested that the gut microbiome as a whole might modulate the viral susceptibility via altering the expression levels of immune activation markers on T cells as well as the prevalence of viral target cells. Indeed, Prevotella may be playing a role here as well because the ratio of Bacterioides to Prevotella species correlated with immune activation. Analysis of specific bacteria will be the topic of future research.

In this study, we did not find a significant difference in Treg cells in the rectal mucosa of the two cohorts. Instead, the two cohorts had different expression levels of immune activation markers, such as CCR5, ki67, and CD38 on different cell subsets, particularly T and myeloid cells, suggesting the possible alteration of these markers on different cell types by gut microbiota or their metabolites. Activated or proliferating CCR5^+^CD4^+^ T cells in the colorectal tissues have been shown to inversely correlate with SIV viral eclipse time^[@R30]^ and to predict increased SIV viral acquisition in the SIV-vaccinated rhesus macaques^[@R29]^. However, in vaccine studies, the vaccine induced antigen-specific immune responses might be a confounder in interpreting the results. In this study, using two groups of naïve macaques, we demonstrated that the immune activation status of the colorectal mucosa was associated with SHIV viral acquisition. Since all the animals were naive, and never exposed previously to SHIV viral antigens, viral-specific immune responses can be ruled out as a factor to determine the challenge outcome.

The finding that naïve animals from different sources demonstrated significantly different HIV/SIV viral susceptibility poses a big problem in HIV/AIDS research. Though we cannot determine the absolute role of each of the examined parameters, the gut microbiome, viral target cells, and mucosal immune activation markers in the rectal should all be measured. One direct implication of this study is the need to set up new criteria for choosing macaques for future HIV/SIV vaccine efficacy or challenge studies. To be matched, the macaques need to have not only similar gender, age and MHC haplotypes, but also similar gut microbiome and prevalence of viral target cells/immune activation in the mucosa. Another important implication is that future studies are needed to take the gut microbiota prevalent in different human populations into account in assessing HIV-1 susceptibility. Stool specimens should be collected for all HIV transmission studies and clinical trials to evaluate this variable. Probiotics may be able to be designed to reduce transmission risk. To the extent that this parameter may be hard to alter in vaccinees, it should be taken into account when comparing vaccine efficacy in different populations with different diets and microbial exposures.

Overall, this study provides novel insights into microbiome-host interactions, and paves the way for potential strategies to reduce susceptibility to HIV-1 transmission or improve vaccine efficacy through microbial manipulation.

Materials and Methods {#S10}
=====================

Animals {#S11}
-------

Two cohorts of adult Indian rhesus macaques (*Macaca mulatta*) were used with the approval of Institutional Animal Care and Use Committees. The macaques were housed at the NCI Animal Facility, Bethesda, MD (Protocols No. VB011 approved by the NCI IACUC). The facility is accredited by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) International. The recommendations of the Standards and Guide for the Care and Use of Laboratory Animals of the United States were closely followed. One cohort of seven naïve macaques (N7 group) was obtained from Morgan Island, while the other 11 naïve macaques were obtained from Alpha Genesis Inc. The detail information of the animals is listed in [Supplementary Table 1](#SD1){ref-type="supplementary-material"}. PBMC and rectal pinch biopsies were collected to measure immune activation. Fecal samples were also collected one week before SHIV challenge.

Viral challenge, and viral load (VL) measurements {#S12}
-------------------------------------------------

The animals were intrarectally exposed to 8 serial SHIVSF162P4 viral challenges (1:35 dilution) at one-week intervals until they were infected. The SHIVS~F162P4~ viral stock was provided by Nancy Miller of the National Institute of Allergy and Infectious Diseases (NIAID). After the viral challenges, SHIV RNA levels were monitored by Advanced BioScience Laboratories, Inc. The cut-off threshold for viral RNA detection was 50 copies/ml.

Flow cytometry analysis of single-cell suspensions from rectal pinches {#S13}
----------------------------------------------------------------------

Single-cell suspensions from rectal pinches were prepared as previously described^[@R30]^. Rectal intraepithelial lymphocytes (IEL) and lamina propria(LP) were collected and subjected to flow cytometry analysis. The single-cell suspensions were first incubated with Fc Receptor blocking reagent (Miltenyi Biotec), followed by staining with viability dye (Invitrogen). The antibody mixtures were then incubated as previously described^[@R27]^. For immune activation, the following antibodies were used: CD45-PerCP, CD3-PE-Cy7, CD4-BV605, CD8-APC-Cy7, CD14-V450, Ki67-APC, HLA-DR PE-Cy5, and CCR5-PE (BD Pharmingen); CD69-Alexa Fluor 700 (Biolegend); and CD38-FITC (STEMCELL Technologies). For detection of Treg and MDSCs, the following antibody mixture were used: CD45-PerCP/Cy5.5, CD3-PE-Cy7, CD4-BV605, CD8-BV785, lin 1-FITC (BD Pharmingen), FOXP3-APC (eBioscience), HLA-DR-APC-Cy7, CD11b-PE-Cy5, CD14-BV711, CD8-BV785, CD25-BV421, CD15-Alexa700 (Biolegend), CD33-PE (Milteny). An LSRII flow cytometer was used for data acquisition. FlowJo software (Tree Star Inc.) was used for data analyses.

Sample processing and Sequencing for gut microbiome {#S14}
---------------------------------------------------

Fecal samples were collected one-week before the serial SHIV viral challenges. DNA was extracted from \~200 mg of stool using the Qiagen DNA Stool Mini Kit. DNA amplification was performed using Eppendorf liquid handling robots. The V4 region of the 16S rDNA gene (515F-806R) was sequenced for 18 samples; generating paired-end, overlapping reads on the Illumina MiSeq platform^[@R45]^.

Chimeric sequences were filtered out of the FASTQ files containing the 16S rRNA gene sequences using the USEARCH (version 8.1.1831)^[@R46]^ utility's UCHIME^[@R47]^ implementation and the 'gold' database (version microbiomeutil-r20110519). The reads, thus filtered, were then binned into operational taxonomic units (OTUs) at 97% similarity using USEARCH's cluster_otus command. QIIME (1.9.1)^[@R48]^ scripts were used to classify and align the obtained OTUs. The assign_taxonomy.py script was used to assign taxonomy using the default RDP method^[@R49]^ and GreenGenes database^[@R50]^.

PBMC stimulation with fecal samples {#S15}
-----------------------------------

Fecal samples from each animal of the N7 and N11 groups were collected one week before SHIV viral challenges. One gram fecal samples (wet weight) were diluted with 1ml of PBS and homogenized for 5min. The homogenized fecal samples were then heat-treated at 56°C for 2h to kill the bacteria. Following heat-treatment, the fecal samples were subjected to a low-spin centrifugation (2000rpm, 2min) to remove large particulate material. The supernatant fractions were collected, and stored at single-use aliquots at −20°C.

Fresh PBMCs from naïve rhesus macaques were suspended in R10 medium to a final concertation of 2 million/ml in a 48-well plate, 500μl per well, at 37°C, 5%CO2. 55μl of supernatant of fecal sample preparations were added to each well, and cultured for 18 or 48 hrs. After stimulation, the cells were washed twice with FACS buffer, and then subjected to flow cytometry analysis as described above. The experiments were performed twice for each time point independently. CD69 was best measured at 18 hours but the other markers shown were highest at 48 hours.

Statistical analysis and Data Visualization {#S16}
-------------------------------------------

Principal component analyses (PCA) were performed with Qlucore Omics Explorer(Qlucore) or SAS. Spearman's correlations were used to analyze the correlations. Mann-Whitney tests were used to compare the difference between N7 and N11 groups (GraphPad Prism software).

Supplementary Material {#S17}
======================

###### 

Supplementary Figure 1. Gating strategy for Treg and MDSCs in rectal LP.

**Supplementary Figure 2. CD14+ MDSCs in N7 group inversely correlated with viral acquisition**. Multi-color flow cytometry techniques were used to measure the frequencies of rectal rectal LP CD25^+^FOXP3^+^ of CD4^+^T cells, CD14+MDSCs and CD15+MDSCs in N7 and N11 cohorts. Correlations between number of viral exposures for the animals to get infected and the rectal LP CD25^+^FOXP3^+^ CD4^+^T cells (a), CD15+MDSCs (b), and CD14+MDSCs (c) were performed using Spearman's tests. The CD14+ MDSC in N7 group inversely correlated with viral acquisition (d). The red dots are the N7 animals, while the black dots are the N11 animals.

Supplementary Figure 3. Gating strategy for CD4+ viral target T cells in rectal IEL

**Supplementary Figure 4 *Firmicutes* did not correlate with numbers of viral exposures for the animals to get infected**. Spearman's test was used to calculate the correlation

**Supplementary Figure 5. Bacteria showed corrections with viral acquisition and immune activation at genus level**. Spearman's tests were used to determine the correlations between number of viral exposures for the animals to get infected and *Mogibacterium* (a), *Hydrogenoanaerobacterium* (b), and *orientia* (c).

**Supplementary Figure 6. Immune activation and gut microbiome did not correlate with age among macaques obtained from the same source**. To determine whether age played any role in determining immune activation and the composition of the gut microbiome, we used data from the N7 group plus another 21 animals (total n = 28 macaques), which were obtained from the same source (Morgan Island) and arrived in the facility in the same shipment at the same time as the N7 group. Correlations between age and viral target cells in rectal mucosa (a) or PBMC (b) were performed using Spearman's tests. Fecal samples from the 21 animals and the N7 groups were collected shortly after they first arrived in the facility before any treatment or challenge. These fecal samples were sequenced, and the data were used for analysis. Correlations between age and the bacterial PCA-1 at genus level (c), or Firmicutes (d), or log ratio of bacteroides/prevotella (e) were assessed by Spearman's tests. Black dots denote the 21 animals, and red triangles denote the N7 group.

**Supplementary Figure 7. Expression levels of Ki67^+^CCR5^+^ on CD4^+^ and CD8^+^T cells**. Naive PBMC were co-cultured with heat-killed gut microbiota samples from each animal of the N7 and N11 groups for 2 days, and the frequencies of Ki67^+^CCR5^+^ cells were measured by flow cytometry. The cells were gated on CD4^+^ (a) or CD8^+^T cells (b).
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![Viral Target cells in the rectal IEL correlated with SHIV acquisition\
a). Viral acquisition curves from two naïve cohorts (N7 and N11) were demonstrated in a low-dose repeated intrarectal challenge model with weekly challenge of SHIVS~F162P4~ virus. b--f). Multi-color flow cytometry techniques were used to measure and compare the frequencies of rectal LP CD25^+^FOXP3^+^ of CD4^+^T cells (b), rectal LP CD14+MDSCs (c) and CD15+MDSCs (d) cells; as well as the viral target cells (Ki67^+^CCR5^+^ in CD4^+^T cells) in PBMC (e) and rectal IEL (f) in N7 and N11 cohorts. Mann-Whitney tests were used for comparisons. g--h) Correlations between viral target cells in PBMC (g) and rectal IEL(H) and number of viral exposures for the animals to get infected were performed using Spearman's tests. Mean±SEM are shown. Triangles denote the N7 group, and filled circles denote the N11 group.](nihms959548f1){#F1}

![The immune activation status was significantly different in the two naive groups\
a) The frequencies of Ki67, CD69, CD38, HLA-DR, and CCR5 in CD4^+^, CD8^+^T cells, and CD14^+^ monocytes, as well as the percentages of the three cell subsets, were used to create a principal component analysis (PCA) plot. b) The signature immune activation markers of the two cohorts (N7 and N11) were shown. Purple dots denote the N7 group, and yellow dots denote the N11 group. c) Immune activation PCA-1 was exported and compared between the N7 and N11 cohorts using a Mann-Whitney test. Mean±SEM are shown. d) Correlation between immune activation PCA-1 and numbers of viral exposures required for the animals to get infected were performed using Spearman's test. The Qlucore Omics Explorer (Qlucore) was used to perform the PCA.](nihms959548f2){#F2}

![The analysis of relative abundance of the fecal microbiome at phylum level revealed that *Firmicutes* was higher in the more viral-resistant cohort, and correlated with viral acquisition\
a) Gut taxa composition from all 18 animals is shown. b) Gut taxa composition from each animal is shown. c) The relative abundance of *Firmicutes* was compared between the two cohorts using a Mann-Whitney test. Correlation between relative abundance of *Firmicutes* and viral target cells and immune activation PCA-1 were performed using Spearman's tests. d) The relative abundance of *Spirochaetes, Proteobacteria, and Bacteroidtes* were compared between the two cohorts using Mann-Whitney tests. Mean±SEM are shown.](nihms959548f3){#F3}

![Principal component analysis (PCA) components at genus level correlated with rectal viral target cells and immune activation PCA-1 (in rectal IEL)\
a) The number of total taxa identified in each animal of the two cohorts were compared using Mann-Whitney test. Mean±SEM are shown. b) PCA plot of gut microbiome at genus level is shown. Red dots denote the N7 group, and black dots denote the N11 group. c) Correlations between PCA component 1 of gut microbiome at genus level versus viral target cells or immune activation PCA-1 were performed using Spearman's test.](nihms959548f4){#F4}

![Relative abundance of the fecal microbiome at genus level was compared in the two naive control groups\
Gut bacterial composition at the genus level. (a--d) Firmicutes, (e--g) Proteobacteria, (h) Bacteroidetes, (i--k) others. Mean±SEM are shown, and statistical analyses were performed using Mann-Whitney tests.](nihms959548f5){#F5}

![The ratio of *bacteroides/prevotella* was higher in the more susceptible cohort and showed corrections with immune activation at genus level\
a) A Mann-Whitney test was used to compare the ratio of *bacteroides/prevotella* between the two cohorts. b--c) Spearman's tests were used to determine the correlations between the ratio of *bacteroides/prevotella* and viral target cells (b) or immune activation (PCA-1) (c) in the rectal IEL.](nihms959548f6){#F6}

![The specific species of *bacteroides and prevotella that* correlated with viral target cells or immune activation PCA-1 were identified\
a) Gut bacterial composition of *prevotella* at the species level. b). The four species of *prevotella* that showed difference in the two cohorts. c). Gut bacterial composition of *bacteroides* at the species level. d). The two species of *bacteroides* that showed differences in the two cohorts. e). The species of *bacteroides* that correlated with viral target cells or immune activation PCA-1 were identified using Spearman's tests. f). Spearman's tests were used to evaluated whether the ratio of specific species of *bacteroides/prevotella* correlated with the viral target cells or immune activation PCA-1 in the rectal IEL. Mean±SEM are shown, and the comparisons of bacterial species between the two cohorts were analyzed using Mann-Whitney tests.](nihms959548f7){#F7}

![Ex vivo co-culture of heat-killed gut microbiota from N7 and N11 groups with naïve PBMCs resulted in significantly different levels of immune activation markers on T cells\
The supernatant of heat-killed gut microbiota from each animal of the N7 and N11 groups were co-cultured with naïve PBMC for 48 hrs as described in Materials & Methods. Cells were harvested and the frequencies of immune activated markers Ki67^+^CCR5^+,^ Ki67^+^, CD38^+^, CD69^+^ and HLA-DR^+^ on CD4^+^ (a--f) and CD8^+^ (g--l) T cells were evaluated using flow cytometry. CD69 on CD4^+^ T cells, which peaks earlier, showed \*p=0.02 for N7 \> N11 at 18hrs after treatment. Means ± SEM are shown, and the comparisons between N7 and N11 groups were analyzed using Mann-Whitney tests.](nihms959548f8){#F8}
